Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia

Lignende værker

• Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia
  af: Thuy Nguyen, et al.
  Udgivet: (2025-03-01)
• Two cases with generalised bullous cutaneous reactions after COVID‐19 mRNA vaccine Moderna (Spikevax®) and Pfizer–BioNTech (Comirnaty®)
  af: Charlotte E. Rinnooy Kan, et al.
  Udgivet: (2024-03-01)
• Applying causal inference and Bayesian statistics to understanding vaccine safety signals using a simulation study
  af: Evelyn Tay, et al.
  Udgivet: (2024-09-01)
• Safety of live attenuated herpes zoster vaccine in Australian adults 70–79 years of age: an observational study using active surveillance
  af: Parveen Fathima, et al.
  Udgivet: (2021-03-01)
• Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023
  af: Jim P Buttery
  Udgivet: (2024-12-01)